PMID- 37193156
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230519
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 15
IP  - 4
DP  - 2023
TI  - Efficacy and safety of glucagon-like peptide-1 receptor agonist combined with 
      sodium-glucose co-transporter-2 inhibitor in the treatment of type 2 diabetes 
      mellitus patients with obesity: a retrospective analysis study.
PG  - 2949-2956
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) and obesity are metabolic diseases 
      characterized by high economic and health burdens. A combination of sodium 
      glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (DAPA) and glucagon-like 
      peptide-1 receptor agonist (GLP1-RA) exenatide (ExQW) has not been explored as a 
      treatment strategy for T2DM patients with obesity. Therefore, this retrospective 
      analysis compared the efficacy and safety of dapagliflozin (DAPA) combined with 
      GLP1-RAs Exenatide (ExQW) and dapagliflozin alone in the treatment of 125 T2DM 
      patients with obesity. METHODS: This study is a retrospective study. From May 
      2018 to December 2019, 62 T2DM patients with obesity were treated with DAPA + 
      ExQW, labeled DAPA + ExQW group. From December 2019 to December 2020, 63 patients 
      with T2DM and obesity were treated with DAPA + placebo, labeled the DAPA + 
      placebo group. DAPA + ExQW group received DAPA at a dose of 10 mg/day plus ExQW 
      at 2 mg/week and DAPA + placebo group was administered with DAPA at a dose of 10 
      mg/day plus a placebo. The primary outcome for the present study was change in 
      HbA1c (%) at different treatment points relative to the baseline. The secondary 
      outcomes included changes in fasting plasma glucose (FPG, mmol/L), systolic blood 
      pressure (SBP, mm/Hg) and body weight (BW, kg). Study outcomes were evaluated at 
      0, 4, 8, 12, 24, and 52 weeks after initial treatment. All P values were 
      two-sided, with a P value less than 0.05 indicating statistical significance. 
      RESULTS: A total of 125 patients completed the present study (62 in the DAPA + 
      ExQW group and 63 in the DAPA group). Patients in the DAPA group showed a 
      significant decrease in the level of HbA1c during the first 4 weeks, but the 
      HbA1c level in this group remained stable for the remaining 48 weeks. Similar 
      results were observed for other variables such as FPG, SBP, and BW. Patients who 
      received a combination of DAPA and ExQW exhibited a continuous decline in the 
      evaluated variables. The decrease in all the variables was greater in the DAPA + 
      ExQW group than that in the DAPA group. CONCLUSIONS: A combination of DAPA and 
      ExQW exerts a synergistic effect in the treatment of T2DM patients with obesity. 
      However, the potential synergistic mechanism of this combination should be 
      studied further.
CI  - AJTR Copyright (c) 2023.
FAU - Wang, Jingpu
AU  - Wang J
AD  - Department of Pharmacy, Affiliated Hospital of Hebei University Baoding 071000, 
      Hebei, China.
FAU - Chen, Yajing
AU  - Chen Y
AD  - Department of Pharmacy, Affiliated Hospital of Hebei University Baoding 071000, 
      Hebei, China.
FAU - Lu, Yan
AU  - Lu Y
AD  - Department of Pharmacy, Affiliated Hospital of Hebei University Baoding 071000, 
      Hebei, China.
FAU - Wang, Heshuai
AU  - Wang H
AD  - Department of Pharmacy, Affiliated Hospital of Hebei University Baoding 071000, 
      Hebei, China.
FAU - Zhao, Yipeng
AU  - Zhao Y
AD  - Department of Pharmacy, Affiliated Hospital of Hebei University Baoding 071000, 
      Hebei, China.
LA  - eng
PT  - Journal Article
DEP - 20230415
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC10182534
OTO - NOTNLM
OT  - GLP1-RA
OT  - SGLT2
OT  - T2DM
COIS- None.
EDAT- 2023/05/17 01:07
MHDA- 2023/05/17 01:08
PMCR- 2023/04/15
CRDT- 2023/05/16 21:20
PHST- 2022/09/06 00:00 [received]
PHST- 2023/03/16 00:00 [accepted]
PHST- 2023/05/17 01:08 [medline]
PHST- 2023/05/17 01:07 [pubmed]
PHST- 2023/05/16 21:20 [entrez]
PHST- 2023/04/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2023 Apr 15;15(4):2949-2956. eCollection 2023.